Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

被引：0

作者：

Kudo, Daisuke ^{[1
]}

Komeno, Takuya ^{[2
]}

Yoshida, Chikashi ^{[2
]}

Tsutsumi, Ikuyo Ota ^{[2
]}

Ohashi, Kazuteru ^{[3
]}

Kakihana, Kazuhiko ^{[3
]}

Kobayashi, Takeshi ^{[3
]}

Doki, Noriko ^{[3
]}

Najima, Yuho ^{[3
]}

Igarashi, Aiko ^{[3
]}

Hori, Mitsuo ^{[4
]}

Okoshi, Yasushi ^{[4
,5
]}

Fujio, Takayuki ^{[4
]}

Shinagawa, Atsushi ^{[6
]}

Yamamoto, Masahide ^{[7
]}

Takano, Hina ^{[8
]}

Kumagai, Takashi ^{[9
]}

Yamamoto, Koh ^{[10
]}

Toyota, Shigeo ^{[11
]}

Nakamura, Yuichi ^{[12
]}

Kojima, Hiroshi ^{[5
,13
]}

机构：

[1] Tokyo Kita Med Ctr, Dept Hematol, Tokyo, Japan

[2] Natl Hosp Org Mito Med Ctr, Dept Hematol, Ibaraki, Japan

[3] Komagome Hosp, Hematol Div, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[4] Ibaraki Cent Hosp, Dept Hematol, Ibaraki, Japan

[5] Univ Tsukuba Hosp, Ibaraki Clin Educ & Training Ctr, Ibaraki, Japan

[6] Hitachi Gen Hosp, Dept Hematol, Ibaraki, Japan

[7] Tokyo Med & Dent Univ Hosp, Dept Hematol, Tokyo, Japan

[8] Japanese Red Cross Musashino Hosp, Dept Hematol, Tokyo, Japan

[9] Ome Municipal Gen Hosp, Dept Hematol, Tokyo, Japan

[10] Yokohama City Minato Red Cross Hosp, Dept Hematol, Yokohama, Kanagawa, Japan

[11] Yokosuka Kyosai Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan

[12] Saitama Med Univ Hosp, Dept Hematol, Saitama, Japan

[13] Ibaraki Cent Hosp, Dept Med Oncol, Ibaraki, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113788

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2160

引用

页数：3

共 50 条

[21] Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients
Silvennoinen, Raija
Kairisto, Veli
Pelliniemi, Tarja-Terttu
Putkonen, Mervi
Anttila, Pekka
Saily, Marjaana
Sikio, Anu
Opas, Jorma
Penttila, Karri
Kuittinen, Taru
Honkanen, Tuomo
Lundan, Tuija
Juvonen, Vesa
Luukkaala, Tiina
Remes, Kari
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (04) : 561 - 564
[22] SEQUENTIAL VAD (VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) AND VTD (BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE TREATMENT WITH BORTEZOMIB FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (A PHASE II TRIAL)
Yoon, S. S.
Kim, H. J.
Lee, D. S.
Sohn, S. K.
Eom, H. S.
Lee, J. L.
Chung, J. S.
Kim, K.
Suh, C. W.
Won, J. H.
Kim, J. S.
Park, J. S.
Kang, H. J.
Seong, C. M.
Kim, C. S.
Lee, S. J.
Lee, J. H.
Yoon, H. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 148 - 148
[23] Final results of a phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): Efficacy and clinical implications of tumor response
Rosinol, L.
Oriol, A.
Mateos, M.
Sureda, A.
Diaz-Mediavilla, J.
Herrero, C.
Liu, X.
de Velde, H. Van
San Miguel, J.
Blade, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[24] Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Cavo, Michele
Pantani, Lucia
Petrucci, Maria Teresa
Patriarca, Francesca
Zamagni, Elena
Donnarumma, Daniela
Crippa, Claudia
Boccadoro, Mario
Perrone, Giulia
Falcone, Antonietta
Nozzoli, Chiara
Zambello, Renato
Masini, Luciano
Furlan, Anna
Brioli, Annamaria
Derudas, Daniele
Ballanti, Stelvio
Dessanti, Maria Laura
De Stefano, Valerio
Carella, Angelo Michele
Marcatti, Magda
Nozza, Andrea
Ferrara, Felicetto
Callea, Vincenzo
Califano, Catello
Pezzi, Annalisa
Baraldi, Anna
Grasso, Mariella
Musto, Pellegrino
Palumbo, Antonio
BLOOD, 2012, 120 (01) : 9 - 19
[25] COST-EFFECTIVENESS OF INDUCTION TREATMENT WITH BORTEZOMIB ADDED TO THALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN GERMANY
van Beurden-Tan, C.
Rosinol, L.
Diels, J.
Wirth, D.
Chirita, O.
Lahuerta, J. J.
Gaugris, S.
Marsh, S.
San Miguel, J.
Spencer, M.
Treur, M.
Blade, J.
VALUE IN HEALTH, 2013, 16 (07) : A409 - A410
[26] Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Harousseau, Jean-Luc
Attal, Michel
Avet-Loiseau, Herve
Marit, Gerald
Caillot, Denis
Mohty, Mohamad
Lenain, Pascal
Hulin, Cyrille
Facon, Thierry
Casassus, Philippe
Michallet, Mauricette
Maisonneuve, Herve
Benboubker, Lotfi
Maloisel, Frederic
Petillon, Marie-Odile
Webb, Iain
Mathiot, Claire
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4621 - 4629
[27] Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Rosinol, Laura
Oriol, Albert
Mateos, Maria Victoria
Sureda, Anna
Garcia-Sanchez, Pedro
Gutierrez, Norma
Alegre, Adrian
Lahuerta, Juan Jose
de la Rubia, Javier
Herrero, Carlos
Liu, Xiangyang
de Velde, Helgi Van
San Miguel, Jesus
Blade, Joan
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4452 - 4458
[28] Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study
Kumar, Shaji
Flinn, Ian W.
Noga, Stephen J.
Hari, Parameswaran
Rifkin, Robert M.
Callander, Natalie Scott
Bhandari, Manish
Wolf, Jeffrey Lee
Gasparetto, Cristina
Krishnan, Amrita
Grosman, Daren D.
Glass, Jonathan
Sahovic, Entezam Asim
Shi, Hongliang
Webb, Iain J.
Richardson, Paul
Rajkumar, S. Vincent
BLOOD, 2008, 112 (11) : 41 - 42
[29] SEQUENTIAL VAD (VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) AND VTD (BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE TREATMENT WITH BORTEZOMIB FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM RESULTS OF PHASE 11 TRIAL
Yoon, S. S.
Kim, H. J.
Lee, D. S.
Eom, H. S.
Jang, J. H.
Chung, J. S.
Kang, H. J.
Kim, C. S.
Kim, K. K.
Lee, J. H.
Lee, S. J.
Min, Y. H.
Seong, C. M.
Sohn, S. K.
Suh, C.
Won, J. H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 86 - 87
[30] Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial
Yoon, Suno-Soo
Kim, Hye Jin
Chung, Joo Seop
Eom, HyeonSeok
Jang, Jun-Ho
Kang, Hye Jin
Kim, Cheol Soo
Kim, Kihyun
Lee, Dongsoon
Lee, Jae Hoon
Lee, Junglim
Lee, Sang Jae
Min, Yoo Hong
Seong, Chu-Myong
Sohn, Sang-Kyun
Suh, Cheolwon
Won, Jong-Ho
BLOOD, 2008, 112 (11) : 1144 - 1144

← 1 2 3 4 5 →